Alkermes (ALKS.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec1

Alkermes Executives Disposed of Company Stocks

22:42

Nov19

Alkermes Increases Bid for Avadel Pharmaceuticals to $2.37 Billion

11:07

Alkermes Increases Bid for Avadel

11:01

Nov17

Truist Financial Analyst Maintains Buy Rating on Alkermes with a Price Target of $55

12:52

Alkermes Announces Lundbeck Proposal as Top Priority

10:47

Nov14

Wells Fargo Downgrades Arkema's Target Price to $37

17:34

Schedules & Filings

Schedules

Filings

Oct28

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 394.19 M, Net Income 82.76 M, EPS 0.49

Jul29

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 390.66 M, Net Income 87.1 M, EPS 0.52

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 306.51 M, Net Income 22.46 M, EPS 0.13

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More